Project Details
Description
PROJECT SUMMARY: GENE EDITING AND EPIGENOMICS CORE
The C-SiG Gene Editing and Epigenomics Core provides current, emerging, and future gene editing and
epigenomic technologies and expertise to center members. The organization and infrastructure of the core
provides essential gene editing and epigenomics expertise and dedicated personnel to advise, interact with,
provide reagents, and directly support C-SiG members in pursuit of the Specific Aims described below. The
core will continue to be led by the Core Director, Dr. Stephen Ekker, who is a well-established molecular
geneticist and gene editor and the Associate Core Director, Dr. Tamas Ordog, who is the founding Director of
the Epigenomics Program of the Mayo Clinic Center for Individualized Medicine (CIM). The CIM Epigenomics
Program develops, implements, and validates epigenomic technology and offering these methods to
investigators. This resource will be leveraged to provide access to a broader segment of the C-SiG
membership to state-of-the-art epigenomic methods at a discounted price, through a C-SiG supported
technologist (50% FTE).
The rapidly evolving disciplines of gene editing and epigenomics provide powerful tools to investigate the
complex coordination of gene expression, which is modulated via a web of mechanistic relationships involving
signaling pathways, transcription factors, and chromatin packaging. Epigenomics analysis when paired with
genetic studies facilitated by gene editing technologies, greatly enhances identification of contributing
molecular signaling pathways and environmental factors. Thus, provision of integrated access to gene editing
and epigenomics expertise, tools, and assays, provides C-SiG members with a powerful and robust set of
technologies to support digestive disease-related cell signaling research.
Accordingly, we have defined and will pursue the following Specific Aims: i) Deliver state-of-the-art gene
editing and epigenomics tools and assays that are needed by C-SiG members, including custom plasmids,
custom nucleases and access to epigenomics assays including chromatin immunoprecipitation coupled with
next generation sequencing (ChIP-seq assays), DNA immunoprecipitation-sequencing-based (DIP-seq); ii)
Accelerate research by connecting members to gene editing and epigenomics-related consultation and
educational opportunities such as seminars, journal clubs, and conferences; iii) Establish cutting-edge
molecular tools and methods for custom genome and RNA editing including new DNA base editors, new RNA
editing tools, and for epitranscriptomics (RNA modification assays). The C-SiG Gene Editing and
Epigenomics Core services have been used by 53% of Center members and supported 29 publications
during the past funding cycle.
Status | Active |
---|---|
Effective start/end date | 9/1/19 → 6/30/24 |
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases: $199,456.00
- National Institute of Diabetes and Digestive and Kidney Diseases: $199,456.00
- National Institute of Diabetes and Digestive and Kidney Diseases: $193,557.00
- National Institute of Diabetes and Digestive and Kidney Diseases: $199,456.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.